Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2001

View Archived Issues

Xenova makes substantial progress during 2000; announces proposed merger with Cantab

Neose Technologies and Novazyme restructure enzyme replacement therapy agreement

First patient inoculated in phase I trial of first AIDS vaccine specifically designed for Africa

Pharmagenesis secures new funding to support development of two drug candidates

Cellegy seeks marketing approval for Rectogesic in South Korea

Celltech and Pharmacia to codevelop and copromote CDP-870

Roche MMPI examined for population pharmacokinetics in osteoarthritis patients

ASCPT news: topical lidocaine proves effective and safe in the treatment of migraine

Ligocyte technology shows promise for antiinfective drug discovery

Patient recruitment begins in phase II trial of E21R for the treatment of CMML

Novel therapeutic approach to rheumatoid arthritis: PPARgamma ligands

Lilly's Zovant appears to be a major advance in the treatment of sepsis

Phase Ib trial of RK-0202 for oral mucositis to commence shortly

Mayo Clinic presents data on new aldehyde dehydrogenase inhibitor at ASCPT meeting

Antiinfective DB-289 successfully completes single-dose phase I trial

Cell Genesys initiates phase I/II trial of GVAX cancer vaccine for multiple myeloma

Pharmacokinetics and tolerability of Ro-09-4889 explored in humans

Pharmacia acquires Sensus; Somavert under review at the FDA

Phase I/II pharmacokinetic and safety data reported at AAD for Atrisone

FDA accepts IntraDose NDA filing

Immunogenic peptides claimed for the treatment of HPV infection

Gene associated with renal disease discovered by Gene Logic

Nucleic acid delivery compounds and compositions for therapeutic use

New Schering compounds useful in diagnosis and therapy of prostate disorders

Indoles and indazoles from NPS Allelix particularly useful for migraine therapy

Novel, orally active androgens designed and tested at Akzo Nobel

EMD-273040: a new cyclic peptide integrin receptor antagonist

Sanofi-Synthelabo presents new CRF antagonists and potential therapeutic uses

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...